Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease

E-ISSN： 1552-4604|55|8|866-874

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.55, Iss.8, 2015-08, pp. : 866-874

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 4, 2015-08 ,pp. : 428-440

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: effectiveness of split‐dose certolizumab pegol for Crohn's disease

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1412-1412

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7‐year PRECiSE 3 study

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 3, 2015-08 ,pp. : 330-342

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Randomized Trial Comparing Disease Activity Measures for the Assessment and Prediction of Response in Rheumatoid Arthritis Patients Initiating Certolizumab Pegol

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 12, 2015-12 ,pp. : 3104-3112

John Wiley & Sons Inc

Access to resources Recommend Favorite

Two Dosing Regimens of Certolizumab Pegol in Patients With Active Rheumatoid Arthritis

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 2, 2015-02 ,pp. : 151-160

John Wiley & Sons Inc

Access to resources Recommend Favorite